Our study, incorporating the latest research and novel GLP‐1 RA‐based drugs, provides robust evidence for the cardiovascular benefits of GLP‐1 RA‐based therapies in overweight and obese populations without diabetes. Here, GLP1R is linked to diabetes mellitus.